CytomX

$7.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.33 (+4.89%) As of 4:58 PM UTC today

Why Robinhood?

You can buy or sell CytomX and other stocks, options, and ETFs commission-free!

About CTMX

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.

CEO
Sean A. McCarthy
Employees
146
Headquarters
South San Francisco, California
Founded
2010
Market Cap
537.77M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
979.02K
High Today
$7.23
Low Today
$6.85
Open Price
$6.85
Volume
649.02K
52 Week High
$15.44
52 Week Low
$6.25

CTMX Earnings

-$0.79
-$0.44
-$0.09
$0.26
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 6, After Hours

You May Also Like

SSAAW
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure